| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
|
N Engl J Med
|
2010
|
9.77
|
|
2
|
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
|
Blood
|
2013
|
8.00
|
|
3
|
Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia.
|
J Clin Oncol
|
2012
|
5.75
|
|
4
|
Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia.
|
J Clin Oncol
|
2007
|
4.93
|
|
5
|
Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
|
Lancet Oncol
|
2009
|
3.91
|
|
6
|
Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma.
|
N Engl J Med
|
2015
|
3.18
|
|
7
|
Chronic graft-versus-host disease: long-term results from a randomized trial on graft-versus-host disease prophylaxis with or without anti-T-cell globulin ATG-Fresenius.
|
Blood
|
2011
|
2.87
|
|
8
|
Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial.
|
Lancet Oncol
|
2011
|
1.81
|
|
9
|
High-dose cytarabine consolidation with or without additional amsacrine and mitoxantrone in acute myeloid leukemia: results of the prospective randomized AML2003 trial.
|
J Clin Oncol
|
2013
|
1.60
|
|
10
|
Value of [18F]fluorodeoxyglucose positron emission tomography in the management of follicular lymphoma: the end of a dilemma?
|
Clin Lymphoma Myeloma
|
2008
|
1.58
|
|
11
|
Pre-transplant positron emission tomography in patients with relapsed Hodgkin lymphoma.
|
Leuk Lymphoma
|
2011
|
1.50
|
|
12
|
MicroRNA biogenesis, functionality and cancer relevance.
|
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub
|
2006
|
1.43
|
|
13
|
IDH2 mutations in patients with acute myeloid leukemia: missense p.R140 mutations are linked to disease status.
|
Leuk Lymphoma
|
2010
|
1.42
|
|
14
|
The persistence of t(14;18)-bearing cells in lymph nodes of patients with follicular lymphoma in complete remission: the evidence for 'a lymphoma stem cell'.
|
Leuk Lymphoma
|
2009
|
1.42
|
|
15
|
Individual differences in the effectiveness of intracoronary bone marrow cell transplantation assessed by gated sestamibi SPECT/FDG PET imaging.
|
J Nucl Cardiol
|
2008
|
1.41
|
|
16
|
MicroRNAs in chronic lymphocytic leukemia pathogenesis and disease subtypes.
|
Leuk Lymphoma
|
2009
|
1.41
|
|
17
|
Missense mutations located in structural p53 DNA-binding motifs are associated with extremely poor survival in chronic lymphocytic leukemia.
|
J Clin Oncol
|
2011
|
1.39
|
|
18
|
Prospective analysis of low-level BCR-ABL1 T315I mutation in CD34 + cells of patients with de novo chronic myeloid leukemia.
|
Leuk Lymphoma
|
2014
|
1.39
|
|
19
|
MYB transcriptionally regulates the miR-155 host gene in chronic lymphocytic leukemia.
|
Blood
|
2011
|
1.32
|
|
20
|
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage.
|
Blood
|
2009
|
1.28
|
|
21
|
Difficulties in using 1,3-{beta}-D-glucan as the screening test for the early diagnosis of invasive fungal infections in patients with haematological malignancies--high frequency of false-positive results and their analysis.
|
J Med Microbiol
|
2010
|
1.21
|
|
22
|
Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT.
|
Blood
|
2005
|
1.18
|
|
23
|
MicroRNA-650 expression is influenced by immunoglobulin gene rearrangement and affects the biology of chronic lymphocytic leukemia.
|
Blood
|
2012
|
1.11
|
|
24
|
Real-time PCR diagnostics failure caused by nucleotide variability within exon 4 of the human cytomegalovirus major immediate-early gene.
|
J Clin Microbiol
|
2007
|
1.11
|
|
25
|
Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet.
|
Blood
|
2012
|
1.11
|
|
26
|
Idiopathic systemic capillary leak syndrome misdiagnosed and treated as polycythemia vera.
|
Acta Haematol
|
2005
|
1.09
|
|
27
|
Mechanism of impaired glucose metabolism during nilotinib therapy in patients with chronic myelogenous leukemia.
|
Haematologica
|
2013
|
1.02
|
|
28
|
Intravenous PLASMA-LYTE as a major cause of false-positive results of platelia Aspergillus test for galactomannan detection in serum.
|
J Clin Microbiol
|
2007
|
0.99
|
|
29
|
Prognostic factors affecting outcome after allogeneic transplantation for hematological malignancies from unrelated donors: results from a randomized trial.
|
Biol Blood Marrow Transplant
|
2012
|
0.97
|
|
30
|
Monitoring trough voriconazole plasma concentrations in haematological patients: real life multicentre experience.
|
Mycoses
|
2012
|
0.96
|
|
31
|
ATM mutations uniformly lead to ATM dysfunction in chronic lymphocytic leukemia: application of functional test using doxorubicin.
|
Haematologica
|
2013
|
0.95
|
|
32
|
Plerixafor to rescue failing chemotherapy-based stem cell mobilization: it's not too late.
|
Leuk Lymphoma
|
2011
|
0.94
|
|
33
|
Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.
|
Leuk Lymphoma
|
2010
|
0.93
|
|
34
|
Rapid detection and identification of mucormycetes from culture and tissue samples by use of high-resolution melt analysis.
|
J Clin Microbiol
|
2010
|
0.92
|
|
35
|
Galactomannan detection in bronchoalveolar lavage fluid for the diagnosis of invasive aspergillosis in patients with hematological diseases-the role of factors affecting assay performance.
|
Int J Infect Dis
|
2011
|
0.91
|
|
36
|
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
|
Am J Hematol
|
2010
|
0.91
|
|
37
|
Mycophenolate mofetil for the treatment of acute and chronic steroid-refractory graft-versus-host disease.
|
Ann Hematol
|
2005
|
0.90
|
|
38
|
Identification of prognostic factors for plerixafor-based hematopoietic stem cell mobilization.
|
Am J Hematol
|
2011
|
0.89
|
|
39
|
Outcome of HLA-matched related allogeneic hematopoietic stem cell transplantation for patients with acute leukemia in first complete remission treated in Eastern European centers. Better results in recent years.
|
Ann Hematol
|
2009
|
0.89
|
|
40
|
Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
|
Clin Cancer Res
|
2013
|
0.89
|
|
41
|
Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
|
Am J Hematol
|
2011
|
0.88
|
|
42
|
Ofatumumab added to dexamethasone in patients with relapsed or refractory chronic lymphocytic leukemia: Results from a phase II study.
|
Am J Hematol
|
2015
|
0.87
|
|
43
|
Multiple productive immunoglobulin heavy chain gene rearrangements in chronic lymphocytic leukemia are mostly derived from independent clones.
|
Haematologica
|
2013
|
0.87
|
|
44
|
Gene expression profiling in follicular lymphoma and its implication for clinical practice.
|
Leuk Lymphoma
|
2010
|
0.84
|
|
45
|
Reactivity of the 1,3-β-D-glucan assay during bacteraemia: limited evidence from a prospective study.
|
Mycoses
|
2012
|
0.84
|
|
46
|
Retrospective analysis of 235 unselected patients with mantle cell lymphoma confirms prognostic relevance of Mantle Cell Lymphoma International Prognostic Index and Ki-67 in the era of rituximab: long-term data from the Czech Lymphoma Project Database.
|
Leuk Lymphoma
|
2013
|
0.84
|
|
47
|
Detection and measurement of fungal burden in a guinea pig model of invasive pulmonary aspergillosis by novel quantitative nested real-time PCR compared with galactomannan and (1,3)-β-D-glucan detection.
|
J Clin Microbiol
|
2011
|
0.84
|
|
48
|
Monitoring of minimal residual disease in acute myeloid leukemia with frequent and rare patient-specific NPM1 mutations.
|
Am J Hematol
|
2010
|
0.84
|
|
49
|
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.
|
Int J Hematol
|
2011
|
0.83
|
|
50
|
Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
|
Cytometry B Clin Cytom
|
2007
|
0.83
|
|
51
|
No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemia.
|
Hematol Oncol
|
2013
|
0.83
|
|
52
|
Combination of fludarabine, amsacrine, and cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with high-risk acute myeloid leukemia.
|
Ann Hematol
|
2013
|
0.82
|
|
53
|
Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse.
|
Haematologica
|
2012
|
0.82
|
|
54
|
The origin of deletion 22q11 in chronic lymphocytic leukemia is related to the rearrangement of immunoglobulin lambda light chain locus.
|
Leuk Res
|
2013
|
0.81
|
|
55
|
Second-line therapies of patients initially treated with fludarabine and cyclophosphamide or fludarabine, cyclophosphamide and rituximab for chronic lymphocytic leukemia within the CLL8 protocol of the German CLL Study Group.
|
Leuk Lymphoma
|
2013
|
0.81
|
|
56
|
Apoptosis in chronic myeloid leukemia cells transiently treated with imatinib or dasatinib is caused by residual BCR-ABL kinase inhibition.
|
Am J Hematol
|
2013
|
0.81
|
|
57
|
Haematopoietic stem cell mobilization with plerixafor and G-CSF in patients with multiple myeloma transplanted with autologous stem cells.
|
Eur J Haematol
|
2011
|
0.80
|
|
58
|
Phase II study of three dose levels of continuous erythropoietin receptor activator (C.E.R.A.) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy.
|
Br J Haematol
|
2007
|
0.80
|
|
59
|
Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activation.
|
Biol Chem
|
2010
|
0.80
|
|
60
|
Presence of heterozygous ATM deletion may not be critical in the primary response of chronic lymphocytic leukemia cells to fludarabine.
|
Eur J Haematol
|
2008
|
0.80
|
|
61
|
Long-term outcomes of autologous transplantation in multiple myeloma: significant survival benefit of novel drugs in post-transplantation relapse.
|
Clin Lymphoma Myeloma
|
2009
|
0.80
|
|
62
|
Role of treatment in the appearance and selection of BCR-ABL1 kinase domain mutations.
|
Mol Diagn Ther
|
2012
|
0.80
|
|
63
|
Experimental model of myocardial infarction: Histopathology and reperfusion damage revisited.
|
Pathol Res Pract
|
2010
|
0.80
|
|
64
|
Gene expression profiling of acute graft-vs-host disease after hematopoietic stem cell transplantation.
|
Exp Hematol
|
2012
|
0.79
|
|
65
|
Identification of novel sequence variations in microRNAs in chronic lymphocytic leukemia.
|
Carcinogenesis
|
2013
|
0.79
|
|
66
|
Salvage lenalidomide in four rare oncological diseases.
|
Tumori
|
2013
|
0.78
|
|
67
|
Micafungin as empirical antifungal therapy in hematological patients: a retrospective, multicenter study in the Czech and Slovak Republics.
|
Leuk Lymphoma
|
2012
|
0.78
|
|
68
|
Quantitative detection of IDH2 mutation for minimal residual disease monitoring in patients with acute myeloid leukemia and its comparison with mutations in NPM1 gene.
|
Leuk Lymphoma
|
2012
|
0.78
|
|
69
|
Explaining survival differences between two consecutive studies with allogeneic stem cell transplantation in patients with chronic myeloid leukemia.
|
J Cancer Res Clin Oncol
|
2014
|
0.78
|
|
70
|
Successful alemtuzumab retreatment in progressive B-cell chronic lymphocytic leukemia: a multicenter survey in 30 patients.
|
Ann Hematol
|
2011
|
0.78
|
|
71
|
Autologous hematopoietic stem cell transplantation in adult acute lymphoblastic leukemia: still not out of fashion.
|
Ann Hematol
|
2009
|
0.78
|
|
72
|
TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods.
|
Tumour Biol
|
2014
|
0.77
|
|
73
|
High frequency of temperature-sensitive mutations of p53 tumor suppressor in acute myeloid leukemia revealed by functional assay in yeast.
|
Int J Oncol
|
2003
|
0.77
|
|
74
|
Invasive mould disease involving the gastrointestinal tract caused by Neosartorya pseudofischeri in a haematological patient.
|
Mycoses
|
2013
|
0.77
|
|
75
|
High expression of lymphocyte-activation gene 3 (LAG3) in chronic lymphocytic leukemia cells is associated with unmutated immunoglobulin variable heavy chain region (IGHV) gene and reduced treatment-free survival.
|
J Mol Diagn
|
2010
|
0.77
|
|
76
|
Detection and treatment of molecular relapse in acute myeloid leukemia with RUNX1 (AML1), CBFB, or MLL gene translocations: frequent quantitative monitoring of molecular markers in different compartments and correlation with WT1 gene expression.
|
Exp Hematol
|
2009
|
0.76
|
|
77
|
Invasive aspergillosis in patients with hematological malignancies in the Czech and Slovak republics: Fungal InfectioN Database (FIND) analysis, 2005-2009.
|
Int J Infect Dis
|
2012
|
0.76
|
|
78
|
Transmission of t(11;14)-positive cells by allogeneic stem cell transplant: 10-year journey to mantle cell lymphoma.
|
Leuk Lymphoma
|
2014
|
0.76
|
|
79
|
Outcome of patients with multiple myeloma and hypertension treated with angiotensin-I-converting enzyme inhibitors during high-dose chemotherapy.
|
Hematol J
|
2005
|
0.76
|
|
80
|
Analysis of mutations in the BCR-ABL1 kinase domain, using direct sequencing: detection of the T315I mutation in bone marrow CD34+ cells of a patient with chronic myelogenous leukemia 6 months prior to its emergence in peripheral blood.
|
Mol Diagn Ther
|
2012
|
0.76
|
|
81
|
Efficacious but insidious: a retrospective analysis of fludarabine-induced myelotoxicity using long-term culture-initiating cells in 100 follicular lymphoma patients.
|
Exp Hematol
|
2009
|
0.76
|
|
82
|
Fludarabine with cytarabine followed by reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation in patients with poor-risk chronic lymphocytic leukemia.
|
Ann Hematol
|
2012
|
0.75
|
|
83
|
Selection of new TP53 mutations by therapy in chronic lymphocytic leukemia.
|
Leuk Res
|
2011
|
0.75
|
|
84
|
Inactivation of p53 and amplification of MYCN gene in a terminal lymphoblastic relapse in a chronic lymphocytic leukemia patient.
|
Cancer Genet Cytogenet
|
2009
|
0.75
|
|
85
|
Reduced-intensity allografting for chronic myeloid leukemia in the first chronic phase.
|
Haematologica
|
2004
|
0.75
|
|
86
|
Evaluation of CD34+ - and Lin- -selected cells from peripheral blood stem cell grafts of patients with lymphoma during differentiation in culture ex vivo using a cDNA microarray technique.
|
Exp Hematol
|
2006
|
0.75
|
|
87
|
Evaluation of response in hepatitic variant of acute liver graft-versus-host disease.
|
Biol Blood Marrow Transplant
|
2010
|
0.75
|
|
88
|
BCR-ABL activity measured by 50% inhibitory concentration for imatinib, p-CrkL/CrkL ratio or p-CrkL ratio in CD34+ cells of patients with chronic myeloid leukemia does not predict treatment response.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
89
|
Current survival measures reliably reflect modern sequential treatment in CML: correlation with prognostic stratifications.
|
Am J Hematol
|
2013
|
0.75
|
|
90
|
Similar efficacy of thalidomide- and bortezomib-based regimens for first relapse of multiple myeloma.
|
Ann Hematol
|
2011
|
0.75
|
|
91
|
Salvage treatment with upfront melphalan 100 mg/m(2) and consolidation with novel drugs for fulminant progression of multiple myeloma.
|
Ann Hematol
|
2009
|
0.75
|
|
92
|
Treatment of chronic myeloid leukemia with autologous transplantation using peripheral blood stem cells or bone marrow cultured in IL-2 followed by IL-2, GM-CSF, and IFN-alpha administration.
|
Med Oncol
|
2003
|
0.75
|
|
93
|
Persistent splenomegaly during imatinib therapy and the definition of complete hematological response in chronic myelogenous leukemia.
|
Am J Hematol
|
2010
|
0.75
|
|
94
|
Clonal heterogeneity in patients with cytogenetically normal acute myeloid leukemia with NPM1 mutations.
|
Leuk Lymphoma
|
2012
|
0.75
|
|
95
|
BCR-ABL1 kinase domain mutational analysis of CD34+ stem/progenitor cells in newly diagnosed CML patients by next-generation sequencing.
|
Am J Hematol
|
2014
|
0.75
|
|
96
|
Clinical and laboratory features of leukemias at the time of diagnosis: an analysis of 1,004 consecutive patients.
|
Am J Hematol
|
2011
|
0.75
|
|
97
|
Failure of molecular diagnostics in chronic myeloid leukemia: an aberrant form of e13a2 BCR-ABL transcript causing false-negative results by standard polymerase chain reaction.
|
Leuk Lymphoma
|
2010
|
0.75
|
|
98
|
Treatment of molecular relapse in patients with acute myeloid leukemia using clofarabine monotherapy.
|
Am J Hematol
|
2011
|
0.75
|
|
99
|
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
|
Leuk Lymphoma
|
2013
|
0.75
|
|
100
|
Anagrelide therapy in pregnancy: report of a case of essential thrombocythemia.
|
Ann Hematol
|
2004
|
0.75
|
|
101
|
A real-time (PCR) for a real life…? Quantitative evaluation of BCL2/IGH in follicular lymphoma and its implications for clinical practice.
|
Exp Hematol
|
2012
|
0.75
|
|
102
|
Comparison of the effect of amphotericin B desoxycholate and amphotericin B colloidal dispersion on renal functions and renal morphology in rats.
|
Nephrology (Carlton)
|
2005
|
0.75
|
|
103
|
The BCR-ABL1 T315I mutation and additional genomic aberrations are dominant genetic lesions associated with disease progression in patients with chronic myelogenous leukemia resistant to tyrosine kinase inhibitor therapy.
|
Leuk Lymphoma
|
2013
|
0.75
|